Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients

Abstract

After more than one year of follow-up, we found no evidence of increased risk of reduced efficacy or increased toxicity after switching from branded to generic lamivudine or zidovudine/lamivudine or efavirenz.